BR112023000906A2 - Agonista parcial do receptor v1a e método de uso - Google Patents
Agonista parcial do receptor v1a e método de usoInfo
- Publication number
- BR112023000906A2 BR112023000906A2 BR112023000906A BR112023000906A BR112023000906A2 BR 112023000906 A2 BR112023000906 A2 BR 112023000906A2 BR 112023000906 A BR112023000906 A BR 112023000906A BR 112023000906 A BR112023000906 A BR 112023000906A BR 112023000906 A2 BR112023000906 A2 BR 112023000906A2
- Authority
- BR
- Brazil
- Prior art keywords
- partial agonist
- present disclosure
- varices
- receiver
- partial
- Prior art date
Links
- 239000004031 partial agonist Substances 0.000 title abstract 5
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 2
- 206010003445 Ascites Diseases 0.000 abstract 1
- 208000000624 Esophageal and Gastric Varices Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 208000032843 Hemorrhage Diseases 0.000 abstract 1
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 206010056091 Varices oesophageal Diseases 0.000 abstract 1
- 206010046996 Varicose vein Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000024170 esophageal varices Diseases 0.000 abstract 1
- 201000010120 esophageal varix Diseases 0.000 abstract 1
- 201000011200 hepatorenal syndrome Diseases 0.000 abstract 1
- 230000036543 hypotension Effects 0.000 abstract 1
- 208000007232 portal hypertension Diseases 0.000 abstract 1
- 231100001274 therapeutic index Toxicity 0.000 abstract 1
- 208000027185 varicose disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
AGONISTA PARCIAL DO RECEPTOR V1A E MÉTODO DE USO. A presente divulgação proporciona novos agonistas parciais de V1a para ativar parcialmente um receptor V1a. O agonista parcial de V1a tem um índice terapêutico de pelo menos 20 (p. ex., pelo menos 30, pelo menos 40, pelo menos 50, pelo menos 60, pelo menos 70, pelo menos 80, pelo menos 90, pelo menos 100). São também proporcionados métodos de tratamento de fibrose hepática, cirrose, hipertensão portal, ascite, varizes esofágicas, varizes fúndicas, hemorragia, hipotensão arterial e/ou síndrome hepatorrenal, incluindo administrar a um sujeito com sua necessidade uma dose terapeuticamente eficaz de uma composição incluindo o(s) agonista(s) parcial(ais) de V1a da presente divulgação, opcionalmente em combinação com um antagonista de V2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063053340P | 2020-07-17 | 2020-07-17 | |
| PCT/US2021/041998 WO2022016064A2 (en) | 2020-07-17 | 2021-07-16 | V1a receptor partial agonist and method of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023000906A2 true BR112023000906A2 (pt) | 2023-02-07 |
Family
ID=79554279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023000906A BR112023000906A2 (pt) | 2020-07-17 | 2021-07-16 | Agonista parcial do receptor v1a e método de uso |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230248800A1 (pt) |
| EP (1) | EP4182021A2 (pt) |
| JP (1) | JP2023535363A (pt) |
| KR (1) | KR20230041029A (pt) |
| CN (1) | CN116323637A (pt) |
| AU (1) | AU2021308675A1 (pt) |
| BR (1) | BR112023000906A2 (pt) |
| CA (1) | CA3186263A1 (pt) |
| IL (1) | IL299805A (pt) |
| MX (1) | MX2023000737A (pt) |
| WO (1) | WO2022016064A2 (pt) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040031072A1 (en) * | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
| US7960336B2 (en) * | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
| JO3109B1 (ar) * | 2012-05-10 | 2017-09-20 | Ferring Bv | منبهات لمستقبلات v1a |
| CA2840941A1 (en) * | 2013-02-05 | 2014-08-05 | Nitto Denko Corporation | Wt1 peptide cancer vaccine composition for transdermal administration |
| US11033601B2 (en) * | 2017-09-14 | 2021-06-15 | The Regents Of The University Of Colorado, A Body Corporate | Selective inhibition of V1b for treating fatty liver |
-
2021
- 2021-07-16 KR KR1020237005292A patent/KR20230041029A/ko active Search and Examination
- 2021-07-16 EP EP21842340.8A patent/EP4182021A2/en active Pending
- 2021-07-16 CA CA3186263A patent/CA3186263A1/en active Pending
- 2021-07-16 MX MX2023000737A patent/MX2023000737A/es unknown
- 2021-07-16 BR BR112023000906A patent/BR112023000906A2/pt unknown
- 2021-07-16 IL IL299805A patent/IL299805A/en unknown
- 2021-07-16 US US18/013,389 patent/US20230248800A1/en active Pending
- 2021-07-16 WO PCT/US2021/041998 patent/WO2022016064A2/en active Application Filing
- 2021-07-16 CN CN202180061156.9A patent/CN116323637A/zh active Pending
- 2021-07-16 JP JP2023503118A patent/JP2023535363A/ja active Pending
- 2021-07-16 AU AU2021308675A patent/AU2021308675A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230248800A1 (en) | 2023-08-10 |
| JP2023535363A (ja) | 2023-08-17 |
| WO2022016064A2 (en) | 2022-01-20 |
| KR20230041029A (ko) | 2023-03-23 |
| AU2021308675A1 (en) | 2023-02-09 |
| CA3186263A1 (en) | 2022-01-20 |
| IL299805A (en) | 2023-03-01 |
| WO2022016064A3 (en) | 2022-02-24 |
| CN116323637A (zh) | 2023-06-23 |
| MX2023000737A (es) | 2023-02-13 |
| EP4182021A2 (en) | 2023-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Djiane et al. | Rapid down-regulation of prolactin receptors in mammary gland and liver | |
| BRPI0511367A (pt) | uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo | |
| CL2010000788A1 (es) | Anticuerpo monoclonal o fragmento de union a antigeno del mismo que se une a integrina alfa-v-beta-6; composicion farmaceutica que lo comprende; uso para tratar o prevenir fibrosis, psoriasis, cancer, daño agudo de pulmon y sindrome de alpont; uso para detectar integrina alfa-v-beta-6 (div. sol. no. 513-03). | |
| DK1280531T3 (da) | Formulering bestående af phentolaminmesylat og anvendelse heraf | |
| CA2358938A1 (en) | Methods for assessing, improving, or maintaining urogenital health in postmenopausal women | |
| ATE516305T1 (de) | Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten | |
| BRPI0712224B8 (pt) | anticorpos de alta afinidade para o receptor de il-6 humano e composições farmacêuticas | |
| DE69819726D1 (de) | Selektive analoge der thyroidhormone | |
| BR112023000906A2 (pt) | Agonista parcial do receptor v1a e método de uso | |
| BR0016089A (pt) | Composição refrigerante, uso de uma composição, processo para produzir refrigeração, e, aparelho de refrigeração | |
| BRPI0511754A (pt) | uso de um composto ou sais ou solvatos do mesmo | |
| ATE542138T1 (de) | Her-2-bindungsantagonisten | |
| CA2524002A1 (en) | Sars-related proteins | |
| Marsigliante et al. | Human larynx expresses isoforms of the oestrogen receptor | |
| BR9808605A (pt) | Processo para a preparação de uma composição asfáltica de classificação aberta, e, uso de uma composição asfáltica | |
| Han et al. | Use of maturity methods to estimate the setting time of concrete containing super retarding agents | |
| BR0213284A (pt) | agentes de realce de afinidade | |
| MX2022006071A (es) | Composiciones y métodos para el tratamiento de enfermedades mediadas por ccr9 utilizando inhibidores de ccr9 y anticuerpos que bloquean anti-tnf-alfa. | |
| Shi et al. | 16-kilodalton heparin binding (fibroblast) growth factor type one appears in a stable 40-kilodalton complex after receptor-dependent internalization. | |
| WO2020101452A1 (ko) | 단백질을 포함하는 안정한 액상 조성물 | |
| JPH0240624B2 (pt) | ||
| IL158817A0 (en) | Epf receptor assays, compounds and therapeutic compositions | |
| Timasheff et al. | The Fractionation of Insulin by Electrophoresis—Convection1 | |
| Toyama et al. | Biophysical, histopathological and pharmacological characterization of crotamine isoforms F22 and F32 | |
| RU2008121941A (ru) | Уплотняющая смесь для гидроизоляции и омоноличивания тоннельных обделок |